Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation

  • Abigail Louise D. Te
  • Tze-Fan Chao
  • Shih-Ann ChenEmail author
Arrhythmias (J.Bunch, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Arrythmias


Purpose of Review

We sought to review the current issues on optimization of anticoagulation in elderly patients with nonvalvular atrial fibrillation (NVAF).

Recent Findings

Advanced age is a risk factor for stroke and as one advances in age, the risk of stroke also increases. One of the many challenges of oral anticoagulation for stroke prevention in the elderly patients with NVAF is the underutilization of anticoagulants. Commonly cited reasons for hesitation by physician in prescribing oral anticoagulants are advanced age, increase risk of bleeding, and the difficulty in maintaining an adequate time in therapeutic range and the need for frequent monitoring for those who are given warfarin. The non-vitamin K antagonist oral anticoagulants (NOAC) have been shown to have similar or superior efficacy, and a better safety profile compared with warfarin due to its wider therapeutic window, low interaction with food, and less frequent monitoring of anticoagulation levels. It is also important to note that renal dysfunction is becoming increasingly common in elderly patients with AF. This poses a therapeutic challenge for physicians due to a higher bleeding risk; thus, renal function should be taken into consideration when prescribing NOACs. Warfarin, on the other hand, remains to be a viable therapeutic option in certain clinical scenarios.


In elderly patients, the choice of oral anticoagulants for stroke prevention in NVAF should be individualized and should include considerations for the best estimate of absolute benefit weighed against bleeding risks in order to optimize anticoagulation.


Atrial fibrillation Oral anticoagulant Elderly Chronic kidney disease Warfarin 



Atrial fibrillation


Creatinine clearance


Intracranial hemorrhage


International normalized ratio


Non-vitamin K antagonist oral anticoagulants


Nonvalvular AF


Oral anticoagulant


Randomized controlled trial


Stroke prevention in atrial fibrillation


Time within therapeutic range


Vitamin K antagonist


Compliance with Ethical Standards

Conflict of Interest

Drs. Te, Chao and Chen declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Lim TW, et al. 2017 Consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33(4):345–67.CrossRefGoogle Scholar
  2. 2.
    Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N.CrossRefGoogle Scholar
  3. 3.
    Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation. 2003;107:2920–5.CrossRefGoogle Scholar
  4. 4.
    Chugh SS, Haymoeller R, Narayan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837–47.CrossRefGoogle Scholar
  5. 5.
    Chao TF, Liu CJ, Tuan TC, Chen TJ, Hsieh MH, Lip GYH, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest. 2018;153(2):453–66.CrossRefGoogle Scholar
  6. 6.
    Lip GY, Nieuwlaat R, Pisters R. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefGoogle Scholar
  7. 7.
    Lip GY. Stroke and bleeding assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013;34(4):1041–9.CrossRefGoogle Scholar
  8. 8.
    Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016;388(10046):806–17.CrossRefGoogle Scholar
  9. 9.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.CrossRefGoogle Scholar
  10. 10.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefGoogle Scholar
  11. 11.
    Maringh R, Lip GY, Lane DA. Stroke prevention in atrial fibrillation patients. Expert Opin Pharmacother. 2010;11(14):2331–50.CrossRefGoogle Scholar
  12. 12.
    • Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risk of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77 Gallagher et al. emphasize on the importance of optimal anticoagulation for stroke reduction and that mortality rates were significantly lower with warfarin when the time spent within therapeutic range is at least 70%. CrossRefGoogle Scholar
  13. 13.
    Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172(8):623–31.CrossRefGoogle Scholar
  14. 14.
    Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103–8.CrossRefGoogle Scholar
  15. 15.
    Chao TF, Chiang CE, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan. Circulation. 2018;138(14):1485–7.CrossRefGoogle Scholar
  16. 16.
    Chiong JR, Cheung RJ. Long-term anticoagulation in the extremely elderly with the newer antithrombotics: safe or sorry? Korean Circ J. 2013;43(5):287–92.CrossRefGoogle Scholar
  17. 17.
    Stöllberger C, Chnupa P, Abzieher C, Länger T, Finsterer J, Klem I, et al. Mortality and rate of stroke or embolism in atrial fibrillation during long term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol. 2004;27:40–6.CrossRefGoogle Scholar
  18. 18.
    van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40:1410–6.CrossRefGoogle Scholar
  19. 19.
    Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30:1223–9.CrossRefGoogle Scholar
  20. 20.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–5.CrossRefGoogle Scholar
  21. 21.
    Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomized controlled trial. BMJ. 2007;335:383.CrossRefGoogle Scholar
  22. 22.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561–4.CrossRefGoogle Scholar
  23. 23.
    • Chao TF, Lip GY, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Relationship of aging and incident co-morbities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71:122–32 Chao et al demonstrated that most AF patients would developed at least 1 new stroke risk factor as they age. The Delta CHA 2 DS 2 -VASc score may be used to predict risk for ischemic stroke, which demonstrate the dynamic nature of stroke risk due to aging and incident comorbidities. CrossRefGoogle Scholar
  24. 24.
    Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.e4.CrossRefGoogle Scholar
  25. 25.
    Tulner LR, van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010;27:39–50.CrossRefGoogle Scholar
  26. 26.
    Gandolfo C, Balestrino M, Burrone A, Del Sette M, Finocchi C. Stroke due to atrial fibrillation and the attitude to prescribing anticoagulation prevention in Italy. A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit. J Neurol. 2008;255:796–802.CrossRefGoogle Scholar
  27. 27.
    Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation – a nationwide descriptive study in Taiwan. Clin Ther. 2008;30:1726–36.CrossRefGoogle Scholar
  28. 28.
    Walker AM, Bennett D. Epidemiology and outcomes in patient s with atrial fibrillation in the United States. Heart Rhythm. 2008;5:1365–72.CrossRefGoogle Scholar
  29. 29.
    Arts DL, Visscher S, Opstelten W, Korevaar JC, Abu-Hanna A, van Weert HC. Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice. PLoS One. 2013;8:e67806.CrossRefGoogle Scholar
  30. 30.
    •• Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: A nationwide cohort study. Circulation. 2018;138:37–47 Chao et al compared the risk of ischemic stroke and ICH in elderly patients (≥ 90 years old) (1) with and without AF without antithrombotic therapy; (2) among AF patients between those without treatment, those taking antiplatelet agents, warfarin; (3) among AF patients taking warfarin and NOACs. The authors found that warfarin was associated with lower risk of ischemic stroke but no difference in ICH risk compared with nontreatment while a positive net clinical benefit was found using warfarin when compared with no antithrombotic therapy or with antiplatelet therapy. When comparing warfarin vs NOAC in elderly patients with AF, there was no significant difference between risks for ischemic stroke but NOAC was found to lower the risk of ICH. They concluded that OACs may be considered for stroke prevention in the elder, with NOACs being a favorable choice. CrossRefGoogle Scholar
  31. 31.
    Biteker M, Basaran Ö, Dogan V, Altun I, Özpamuk Karadeniz F, Tekkesin AI, et al. Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation: results from the ReAl-life Multicenter Survey Evaluation Stroke Study. J Am Geriatr Soc. 2017;65:1684–90.CrossRefGoogle Scholar
  32. 32.
    Yamashita Y, Hamatani Y, Esato M, Hun YH, Tsuji H, Wada H, et al. Clinical characteristics and outcomes in extreme elderly (age >85 years) Japanese patients with atrial fibrillation: the Fushimi AF Registry. Chest. 2016;149:401–12.CrossRefGoogle Scholar
  33. 33.
    Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet. 2007;370:493–503.CrossRefGoogle Scholar
  34. 34.
    Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151–6.CrossRefGoogle Scholar
  35. 35.
    Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297–305.CrossRefGoogle Scholar
  36. 36.
    van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the stroke prevention investigators. Stroke. 2009;40:1410–6.CrossRefGoogle Scholar
  37. 37.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.CrossRefGoogle Scholar
  38. 38.
    Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014;63:747–62.CrossRefGoogle Scholar
  39. 39.
    Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60:1487–92.CrossRefGoogle Scholar
  40. 40.
    Ekerstad N, Bylin K, Karlson BW. Early re-hospitalizations of frail elderly patients – the role of medications: clinical, prospective, observational trial. Drug Healthc Patient Saf. 2017;9:77–88.CrossRefGoogle Scholar
  41. 41.
    Patti G, Lucerna M, Pecen L, et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events- European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6:e005657.CrossRefGoogle Scholar
  42. 42.
    Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38:156–62.CrossRefGoogle Scholar
  43. 43.
    Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7:915–26.CrossRefGoogle Scholar
  44. 44.
    Thompson LE, Maddox TM, Lei L, et al. Sex differences in the sue of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR) PINNACLE registry. J Am Heart Assoc. 2017;6:1–10.CrossRefGoogle Scholar
  45. 45.
    Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:163–82.CrossRefGoogle Scholar
  46. 46.
    Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-Vasc? Circulation. 2018;137:832–40.CrossRefGoogle Scholar
  47. 47.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRefGoogle Scholar
  48. 48.
    Fawzy A, Lip GYH. Anti-coagulation in elderly patients with non-valvular atrial fibrillation: a balancing act. Heart Rhythm. 2018.
  49. 49.
    Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.CrossRefGoogle Scholar
  50. 50.
    Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–41.CrossRefGoogle Scholar
  51. 51.
    Gateman D, Trojnar ME, Agarwal G. Warfarin anticoagulation for atrial fibrillation in community-based practice. Can Fam Physician. 2017;63:e425–31.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144:1555–63.CrossRefGoogle Scholar
  53. 53.
    Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014;146:719–26.CrossRefGoogle Scholar
  54. 54.
    Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127:1083–8.CrossRefGoogle Scholar
  55. 55.
    Hylek E, Go A, Chang Y. Increasing age is not associated with poorer anticoagulation control in outpatients with nonvalvular atrial fibrillation. J Am Geriatr Soc. 2000;48:S58.Google Scholar
  56. 56.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefGoogle Scholar
  57. 57.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefGoogle Scholar
  58. 58.
    Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban and warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefGoogle Scholar
  59. 59.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefGoogle Scholar
  60. 60.
    Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103:1015–23.CrossRefGoogle Scholar
  61. 61.
    Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138–46.CrossRefGoogle Scholar
  62. 62.
    Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–72.CrossRefGoogle Scholar
  63. 63.
    Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIM 48 trial. J Am Heart Assoc. 2016;5:e003432.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: Niigata preventive medicine study. Am Heart J. 2009;158:629–36.CrossRefGoogle Scholar
  65. 65.
    •• Chan KE, Giugliano RP, Patel MR, Abramson S, Jardine M, Zhao S, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67:2888–99 Chan et al. reviewed the pharmacokinetic data on NOACs in patients with severe renal impairment and those on hemodialysis. They presented the data in terms of safety and efficacy of NOACs for stroke prevention in this group of patients with AF especially that the randomized controlled trial of each NOACs excluded patients with severe renal impairment and those on hemodialysis. CrossRefGoogle Scholar
  66. 66.
    Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.CrossRefGoogle Scholar
  67. 67.
    Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2012;52:1195–255.CrossRefGoogle Scholar
  68. 68.
    Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation. A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961–70.CrossRefGoogle Scholar
  69. 69.
    Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.CrossRefGoogle Scholar
  70. 70.
    Siontis K, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138:1519–29.CrossRefGoogle Scholar
  71. 71.
    Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Xhang D, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628–36.CrossRefGoogle Scholar
  72. 72.
    Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EA, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF TIME 48 trial. Circulation. 2016;134:24–36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Abigail Louise D. Te
    • 1
    • 2
  • Tze-Fan Chao
    • 1
    • 3
  • Shih-Ann Chen
    • 1
    • 3
    Email author
  1. 1.Heart Rhythm Center, Division of Cardiology, Department of MedicineTaipei Veterans General HospitalTaipeiTaiwan
  2. 2.Heart InstituteSt. Luke’s Medical Center - Global CityTaguigPhilippines
  3. 3.Institute of Clinical Medicine and Cardiovascular Research CenterNational Yang-Ming UniversityTaipeiTaiwan

Personalised recommendations